Editorial CARの扉を開くカギ 2017年10月11日 Nature Biotechnology 35, 10 doi: 10.1038/nbt.3993 Although Kymriah's approval represents a landmark for chimeric antigen receptor T-cell (CAR-T) therapy in B-cell malignancies, solid tumors remain a formidable challenge. Full text PDF 目次へ戻る
